Alerts will be sent to your verified email
Verify EmailZIMLAB
Zim Laboratories
|
Venus Remedies
|
Gufic Biosciences
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
11.2 % | n/a | 1.06 % |
Financials
|
|||
5 yr Average ROE
|
6.88 % | 3.75 % | 26.14 % |
5yr average Equity Multiplier
|
1.92 | 1.64 | 2.82 |
5yr Average Asset Turnover Ratio
|
0.96 | 0.78 | 1.1 |
5yr Avg Net Profit Margin
|
3.75 % | 2.2 % | 9.03 % |
Price to Book
|
2.35 | 1.02 | 6.83 |
P/E
|
32.46 | 17.44 | 42.23 |
5yr Avg Cash Conversion Cycle
|
35.7 Days | 62.86 Days | -18.02 Days |
Inventory Days
|
67.21 Days | 110.85 Days | 77.22 Days |
Days Receivable
|
97.06 Days | 37.87 Days | 81.36 Days |
Days Payable
|
149.76 Days | 50.32 Days | 175.58 Days |
5yr Average Interest Coverage Ratio
|
3.65 | 42.3 | 10.3 |
5yr Avg ROCE
|
13.04 % | 5.53 % | 33.27 % |
5yr Avg Operating Profit Margin
|
12.88 % | 12.68 % | 17.37 % |
5 yr average Debt to Equity
|
0.42 | 0.38 | 0.73 |
5yr CAGR Net Profit
|
39.21 % | n/a | 29.43 % |
5yr Average Return on Assets
|
3.71 % | 3.42 % | 10.17 % |
Shareholdings
|
|||
Promoter Holding
|
33.26 % | 41.76 % | 72.51 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 5.87 % | 6.76 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -6.16 % |
Zim Laboratories
|
Venus Remedies
|
Gufic Biosciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Capex
|
Capex
|
-
|
-
|
Customer Segment
|
Customer Segment
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|